InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (16 ops.)
Insider track record
OtherDisclosed buys
0
Disclosed sells
16
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by UBS Oncology Impact Fund L.P.. Insider active across 2 companies, notably Cullinan Oncology, Inc.. Aggregated, 17 reports have been recorded. Breakdown: 0 buy · 16 sells. Total volume traded: €5.3m. History available since 11 August 2021. The latest transaction was disclosed on 1 June 2023 (J). Regulator: SEC (Form 4). All data is free.
Declarations17 total
3,370,982 shares0Common StockSEC:0001209191-23-034346:0
3,124 shares@ US$29.060.0080% mcap1.5% of flowCommon StockSEC:0001209191-21-056914:0
3,124 shares@ US$29.061.5% of flowCommon StockSEC:0001209191-21-056914
7,106 shares@ US$29.170.018% mcap3.3% of flowCommon StockSEC:0001209191-21-056411:0
7,106 shares@ US$29.173.3% of flowCommon StockSEC:0001209191-21-056411
13,727 shares@ US$29.350.035% mcap6.4% of flowCommon StockSEC:0001209191-21-055726:0
13,727 shares@ US$29.356.4% of flowCommon StockSEC:0001209191-21-055726
12,731 shares@ US$29.600.033% mcap6.0% of flowCommon StockSEC:0001209191-21-055203:0
12,731 shares@ US$29.606.0% of flowCommon StockSEC:0001209191-21-055203
1,285 shares@ US$29.430.0033% mcap0.6% of flowCommon StockSEC:0001209191-21-054518:0
1,285 shares@ US$29.430.6% of flowCommon StockSEC:0001209191-21-054518
13,357 shares@ US$29.090.034% mcap6.2% of flowCommon StockSEC:0001209191-21-054093:0
13,357 shares@ US$29.096.2% of flowCommon StockSEC:0001209191-21-054093
53,359 shares@ US$29.1124.9% of flowCommon StockSEC:0001209191-21-053380
53,359 shares@ US$29.110.14% mcap24.9% of flowCommon StockSEC:0001209191-21-053380:0
2,510 shares@ US$29.050.0064% mcap1.2% of flowCommon StockSEC:0001209191-21-051148:0
2,510 shares@ US$29.051.2% of flowCommon StockSEC:0001209191-21-051148
17 of 17 declarations
About UBS Oncology Impact Fund L.P.
UBS Oncology Impact Fund L.P. is an investor in Cullinan Oncology, Inc.
